Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherNEUROPHARMACOLOGY

ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A Novel Cholinergic Channel Modulator with Effects on Cognitive Performance in Rats and Monkeys

Michael W. Decker, Anthony W. Bannon, Peter Curzon, Karen L. Gunther, Jorge D. Brioni, Mark W. Holladay, Nan-Horng Lin, Yihong Li, Jerome F. Daanen, Jerry J. Buccafusco, Mark A. Prendergast, William J. Jackson and Stephen P. Arneric
Journal of Pharmacology and Experimental Therapeutics October 1997, 283 (1) 247-258;
Michael W. Decker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony W. Bannon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Curzon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen L. Gunther
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge D. Brioni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark W. Holladay
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nan-Horng Lin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yihong Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerome F. Daanen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerry J. Buccafusco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark A. Prendergast
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William J. Jackson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen P. Arneric
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride], a novel ligand at neuronal nicotinic acetylcholine receptors with reduced adverse effects and improved oral bioavailability relative to (−)-nicotine, was tested in a variety of cognitive tests in rats and monkeys. Administered acutely, ABT-089 only marginally improved the spatial discrimination water maze performance of septal-lesioned rats. However, more robust improvement (45% error reduction on the last training day) was observed when ABT-089 was administered continuously via subcutaneous osmotic pumps (minimum effective dose: 1.3 μmol/kg/day). Continuous infusion of (−)-nicotine produced comparable improvement in the spatial discrimination water maze performance of septal-lesioned rats, but a 40-fold higher dose of (−)-nicotine was required (62 μmol/kg/day). Continuous infusion of ABT-089 to aged rats enhanced spatial learning in a standard Morris water maze, as indexed by spatial bias exhibited during a probe trial conducted after 4 days of training, but not when they were subsequently trained in a two-platform spatial discrimination water maze. The compound induced a small impairment in young rats on the standard water maze, but not on the two-platform task. A probe trial conducted after additional training in the standard water maze revealed no age or drug effects. ABT-089 did not affect performance of either the aged or young rats during inhibitory (passive) avoidance training. Also, continuous infusion of ABT-089 did not affect responses to acoustic startle or prepulse inhibition of acoustic startle in young, aged or septal-lesioned rats and did not affect locomotor activity in either sham-lesioned or septal-lesioned rats. In monkeys, acute administration of ABT-089 modestly improved the delayed matching-to-sample performance of mature, adult monkeys and more robustly improved performance in aged monkeys. Improved performance in the aged monkeys was restricted to the longest delay intervals and was not accompanied by changes in response latencies.

Footnotes

  • Send reprint requests to: Michael W. Decker, Dept. 47W, Bldg. AP-9A/LL, 100 Abbott Park Rd., Abbott Laboratories, Abbott Park, IL 60064-3500. .

  • Abbreviations:
    AD
    Alzheimer’s Disease
    ANCOVA
    analysis of covariance
    ANOVA
    analysis of variance
    ChAT
    choline acetyltransferase
    ChCM
    cholinergic channel modulator
    DMTS
    delayed matching to sample
    nAChR
    nicotinic acetylcholine receptor
    PPI
    prepulse inhibition
    • Received December 10, 1996.
    • Accepted June 26, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 283, Issue 1
1 Oct 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A Novel Cholinergic Channel Modulator with Effects on Cognitive Performance in Rats and Monkeys
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherNEUROPHARMACOLOGY

ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A Novel Cholinergic Channel Modulator with Effects on Cognitive Performance in Rats and Monkeys

Michael W. Decker, Anthony W. Bannon, Peter Curzon, Karen L. Gunther, Jorge D. Brioni, Mark W. Holladay, Nan-Horng Lin, Yihong Li, Jerome F. Daanen, Jerry J. Buccafusco, Mark A. Prendergast, William J. Jackson and Stephen P. Arneric
Journal of Pharmacology and Experimental Therapeutics October 1, 1997, 283 (1) 247-258;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
OtherNEUROPHARMACOLOGY

ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A Novel Cholinergic Channel Modulator with Effects on Cognitive Performance in Rats and Monkeys

Michael W. Decker, Anthony W. Bannon, Peter Curzon, Karen L. Gunther, Jorge D. Brioni, Mark W. Holladay, Nan-Horng Lin, Yihong Li, Jerome F. Daanen, Jerry J. Buccafusco, Mark A. Prendergast, William J. Jackson and Stephen P. Arneric
Journal of Pharmacology and Experimental Therapeutics October 1, 1997, 283 (1) 247-258;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • P-Glycoprotein Apical Efflux Ratio for Compound Optimization
  • Pharmacology of Carbamate Insecticides at Melatonin Receptors
  • Metalloporphyrins modify disease outcomes in parkinsonism
Show more Neuropharmacology

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics